vs
Side-by-side financial comparison of PROSPERITY BANCSHARES INC (PB) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
PROSPERITY BANCSHARES INC is the larger business by last-quarter revenue ($367.6M vs $177.4M, roughly 2.1× Pacira BioSciences, Inc.). PROSPERITY BANCSHARES INC runs the higher net margin — 31.6% vs 1.6%, a 30.0% gap on every dollar of revenue. Over the past eight quarters, PROSPERITY BANCSHARES INC's revenue compounded faster (19.2% CAGR vs -0.2%).
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PB vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $367.6M | $177.4M |
| Net Profit | $116.3M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 31.6% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | -10.7% | — |
| EPS (diluted) | $1.16 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $367.6M | $177.4M | ||
| Q4 25 | $275.0M | $196.9M | ||
| Q3 25 | $273.4M | $179.5M | ||
| Q2 25 | $267.7M | $181.1M | ||
| Q1 25 | $265.4M | $168.9M | ||
| Q4 24 | $267.8M | $187.3M | ||
| Q3 24 | $261.7M | $168.6M | ||
| Q2 24 | $258.8M | $178.0M |
| Q1 26 | $116.3M | $2.9M | ||
| Q4 25 | $139.9M | — | ||
| Q3 25 | $137.6M | $5.4M | ||
| Q2 25 | $135.2M | $-4.8M | ||
| Q1 25 | $130.2M | $4.8M | ||
| Q4 24 | $130.1M | — | ||
| Q3 24 | $127.3M | $-143.5M | ||
| Q2 24 | $111.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 65.1% | 1.2% | ||
| Q3 25 | 64.4% | 3.5% | ||
| Q2 25 | 64.3% | 4.7% | ||
| Q1 25 | 62.7% | 1.2% | ||
| Q4 24 | 62.0% | 13.2% | ||
| Q3 24 | 62.1% | -82.8% | ||
| Q2 24 | 55.2% | 15.9% |
| Q1 26 | 31.6% | 1.6% | ||
| Q4 25 | 50.9% | — | ||
| Q3 25 | 50.3% | 3.0% | ||
| Q2 25 | 50.5% | -2.7% | ||
| Q1 25 | 49.1% | 2.8% | ||
| Q4 24 | 48.6% | — | ||
| Q3 24 | 48.6% | -85.1% | ||
| Q2 24 | 43.1% | 10.6% |
| Q1 26 | $1.16 | $0.07 | ||
| Q4 25 | $1.48 | $0.05 | ||
| Q3 25 | $1.45 | $0.12 | ||
| Q2 25 | $1.42 | $-0.11 | ||
| Q1 25 | $1.37 | $0.10 | ||
| Q4 24 | $1.36 | $0.38 | ||
| Q3 24 | $1.34 | $-3.11 | ||
| Q2 24 | $1.17 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.2B | $653.9M |
| Total Assets | $43.6B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $8.2B | $653.9M | ||
| Q4 25 | $7.6B | $693.1M | ||
| Q3 25 | $7.7B | $727.2M | ||
| Q2 25 | $7.6B | $757.8M | ||
| Q1 25 | $7.5B | $798.5M | ||
| Q4 24 | $7.4B | $778.3M | ||
| Q3 24 | $7.4B | $749.6M | ||
| Q2 24 | $7.3B | $879.3M |
| Q1 26 | $43.6B | $1.2B | ||
| Q4 25 | $38.5B | $1.3B | ||
| Q3 25 | $38.3B | $1.3B | ||
| Q2 25 | $38.4B | $1.5B | ||
| Q1 25 | $38.8B | $1.6B | ||
| Q4 24 | $39.6B | $1.6B | ||
| Q3 24 | $40.1B | $1.5B | ||
| Q2 24 | $39.8B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
